Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
|Videos|October 19, 2015
Optimizing the Specialty Drug Pathway from Manufacturers to Pharmacies
Author(s)Davy James, Managing Editor
Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Advertisement
Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Advertisement
Related to this article
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5